Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)

Bibliographic Details
Main Authors:	Patel, Sapna, Milhem, Mohammed, Hallmeyer, Sigrun, Daniels, Gregory, Cranmer, Lee, Taback, Bret, Flaherty, Lawrence, Aung, Sandra, Lowder, James, Sharfman, William
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288743/

Similar Items

A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
by: Clark, Joseph, et al.
Published: (2014)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
by: Buchbinder, Elizabeth I., et al.
Published: (2016)

Racial Proclivities to Disease
Published: (1909)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
by: Kaufman, Howard L, et al.
Published: (2014)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
by: Amaria, Rodabe N, et al.
Published: (2015)

Membrane Stress Proclivities in the Mammalian Labyrinth
by: Pender, Daniel J.
Published: (2014)

Prakruti genomics and prameha-proclivity: relevance to metabolic syndrome
by: Vaidya, Ashok DB
Published: (2014)

Proclivity of political participation among Wakaidesu (????) Japanese
by: Part Time Mohd Zulhimi bin Zolkefali
Published: (2017)

Cultural background shapes spatial reference frame proclivity
by: Goeke, Caspar, et al.
Published: (2015)

The Proclivity of Women to Cancerous Diseases, and to Certain Benign Tumours
Published: (1892)

Correlates of academic misconduct and CSR proclivity of students
by: Stephen, K. Nkundabanyanga, et al.
Published: (2014)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
by: Jeter, Joanne M., et al.
Published: (2012)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
by: Patel, Sapna P, et al.
Published: (2011)

Ipilimumab
Published: (2012)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
by: Middleton, Mark R., et al.
Published: (2016)

Dietary proclivities of Paranthropus robustus from Swartkrans, South Africa
by: L’Engle Williams Frank
Published: (2015-03-01)

Inherited proclivity: When should neurogenetics mitigate moral culpability for purposes of sentencing?
by: Segal, J Bradley
Published: (2016)

Effects of relational proclivity and marketing intelligence on new product development
by: Kevin, J. Trainor, et al.
Published: (2013)

Ipilimumab: Melanoma and beyond
by: Patel, Vishal, et al.
Published: (2011)

Use of ipilimumab in the treatment of melanoma
by: Acharya, Utkarsh H, et al.
Published: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
by: Ban-Hoefen, Makiko, et al.
Published: (2016)

Ipilimumab-induced colonic perforation
by: Burdine, Lyle, et al.
Published: (2014)

Infectious Colitis Associated With Ipilimumab Therapy
by: McCutcheon, Jessica L., et al.
Published: (2014)

Ipilimumab in patients with melanoma and autoimmune disease
by: Kyi, Chrisann, et al.
Published: (2014)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
by: Wong, Michael KK, et al.
Published: (2015)

Tribal proclivity and its effects on the cooperate existence of Nigeria in the centenary era: an Islamic perspective
by: Muhammad, Usman Jimoh
Published: (2015)

Tribal proclivity and its effects on the cooperate existence of Nigeria in the centenary era: an Islamic perspective
by: Nik Zainun
Published: (2015)

Insecure Attachment Style and Dysfunctional Sexual Beliefs Predict Sexual Coercion Proclivity in University Men
by: Dang, Silvain S, et al.
Published: (2015)

Inflammasome effects in GvHD
by: Koehn, Brent H., et al.
Published: (2015)

High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma
by: Mohiuddin, Majid, et al.
Published: (2015)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
by: Ascierto, Paolo Antonio, et al.
Published: (2013)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
by: Dummer, Reinhard, et al.
Published: (2015)

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
by: Wang, Wenshi, et al.
Published: (2012)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
by: Della Vittoria Scarpati, Giuseppina, et al.
Published: (2014)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
by: de Gruijl, T, et al.
Published: (2014)

Ipilimumab and radiation therapy for melanoma brain metastases
by: Silk, Ann W, et al.
Published: (2013)

Ipilimumab for advanced melanoma: A pharmacologic perspective
by: Trinh, Van Anh, et al.
Published: (2013)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab
by: Kropp, Lauren M., et al.
Published: (2016)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
by: Tsai, Katy K., et al.
Published: (2015)